Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 10, 2019

View Archived Issues

Prokarium receives funding from Wellcome for clinical development of lead vaccine program

Dermira initiates phase III program of lebrikizumab in atopic dermatitis

First patient enrolled in phase II study of bavituximab plus pembrolizumab in gastric cancer

Mithra initiates phase III E4 Comfort clinical program for Donesta

Topline results presented for phase Ib study of ANX-007 in patients with glaucoma

Novel bispecific antibody 4224 shows in vivo efficacy in tumors expressing high levels of EpCAM

Improved gamma-gamma cross-linking could hep prevent thromboembolic diseases

Results from OS analysis of KATE2 study of atezolizumab plus T-DM1 in HER2+ advanced BC

RCC2 as a novel therapeutic target in glioblastoma

Chinese investigators patent ROCK inhibitors

Roche divulges new MGL inhibitors

Beijing Tide Pharmaceutical synthesizes AGTR2 antagonists

Evelo Biosciences presents new Tyzzerella nexilis bacterial compositions

Affimed Therapeutics divulges EGFR- and CD16A-targeting proteins

AgenTus Therapeutics develops T-cell receptor candidate targeting NY-ESO-1

FDA approves PF-708 for osteoporosis

DSMB recommends continuation of phase IIa study of montelukast VersaFilm in Alzheimer's disease

New phase I study evaluates birinapant and radiation therapy in head and neck cancer

MIF may contribute to disseminated coccidioidomycosis susceptibility

Rubius initiates first-in-human study of RTX-135 for phenylketonuria

Calling bias sinks CCR5 work, but is "likely unique" to variant

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 7, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...